Chemotherapy Emerges as 1st Line Mesothelioma Therapy in Belgian Trial

In Belgium, researchers have discovered that pleural mesothelioma patients survived longest after receiving chemotherapy treatment, compared to other forms of anti-tumour therapy. Findings were published in the Lung Cancer Journal.[i]

More than 1,400 patients, diagnosed with malignant pleural mesothelioma (MPM) between 2004 and 2012, were randomly selected from the Belgian Cancer Registry to take part in the study.

The MPM patients underwent different types of treatment, including multimodal radical surgery and tumour-directed cisplatin-permetrexed chemotherapy (69% of patients).

Researchers identified that chemotherapy combination therapy emerged as a potential 1st line therapy. The best survival results were observed in younger, female patients, with epithelioid MPM.

In other mesothelioma-related news, a phase 1 clinical trial of a novel mesothelioma and ovarian cancer drug, MCY-M11, has begun at the National Cancer Institute at the National Institutes of Health and Washington University at St. Louis, USA. It is hoped that this drug will inhibit tumour growth and extend survival in patients.[ii]

Although MCY-M11 development is still premature, in laboratory studies involving animal test subjects, the more injections received, the greater the effect.


[i] Rosskamp, Michael et al. ‘Real-life treatment practice for malignant pleural mesothelioma in Belgium’ Lung Cancer (2018) Volume 125, 258 – 264 <> accessed 20 November 2018.

[ii] ‘Clinical Testing of Anti-Tumor Mesothelioma Drug Begins’ (14 November 2018 <> accessed 22 November 2018.